TrialArthritis & rheumatology (Hoboken, N.J.)2020

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Michael F Robinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.